A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas

OBJECTIVE: Alterations in the methylation state of pseudogenes may serve as clinically useful biomarkers of glioblastomas (GBMs) that do not have glioma-CpG island methylator phenotype (G-CIMP). METHODS: Non-G-CIMP GBM datasets were included for evaluation, and a RISK-score signature was determined...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Bowen, Wang, Jiu, Liu, Fangfang, Li, Rui, Hu, Weihong, Etcheverry, Amandine, Aubry, Marc, Mosser, Jean, Yin, Anan, Zhang, Xiang, Wu, Yuanming, Chen, Kun, He, Yalong, Wang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194959/
https://www.ncbi.nlm.nih.gov/pubmed/35712126
http://dx.doi.org/10.1155/2022/6345160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194959/
https://www.ncbi.nlm.nih.gov/pubmed/35712126
http://dx.doi.org/10.1155/2022/6345160

Ejemplares similares